<DOC>
	<DOCNO>NCT00064051</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy gemcitabine use different way stop tumor cell divide stop grow die . 3-AP may stop growth tumor cell block enzymes necessary tumor cell growth may help gemcitabine kill cancer cell make sensitive drug . PURPOSE : This phase II trial study well give gemcitabine together 3-AP work treat patient unresectable metastatic pancreatic cancer .</brief_summary>
	<brief_title>3-AP Gemcitabine Treating Patients With Unresectable Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine objective response rate ( partial complete response ) patient unresectable metastatic pancreatic cancer treat 3-AP gemcitabine . - Determine progression-free interval survival patient treat regimen . - Determine safety feasibility regimen patient . OUTLINE : This multicenter study . - Stage I : Patients receive 3-AP IV 4 hour gemcitabine IV 30 minute day 1 , 8 , 15 . Treatment repeat every 4 week 12 course absence disease progression unacceptable toxicity . - Stage II : Patients receive high dose 3-AP IV continuously 24 hour day 1 , 8 , 15 . Within 1 hour complete 3-AP administration , patient receive gemcitabine IV 30 minute day 2 , 9 , 16 . Treatment repeat every 4 week 12 course absence disease progression unacceptable toxicity . Patients follow 1 month , every 2 month 6 month , every 3 month 18 month . PROJECTED ACCRUAL : A total 50-95 patient accrue study within 18-24 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm pancreatic cancer Unresectable metastatic disease Measurable disease Outside prior radiation port OR within prior radiation port evidence disease progression radiotherapy No CNS metastases PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy More 3 month Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9 g/dL ( transfusion allow ) Hepatic Bilirubin great 2.0 mg/dL AST ALT great 3 time upper limit normal ( ULN ) ( 5 time ULN presence liver metastasis ) Chronic viral hepatitis allow Renal Creatinine great 2.0 mg/dL Cardiovascular No myocardial infarction within past 3 month No uncontrolled congestive heart failure No uncontrolled coronary artery disease No uncontrolled arrhythmias Pulmonary No dyspnea rest No dependence supplemental oxygen Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation No malignancy except follow : Carcinoma situ cervix treat cone biopsy resection Nonmetastatic basal cell squamous cell skin cancer Any stage I malignancy curatively resect 5 year ago No active infection No known suspect glucose6phosphate dehydrogenase deficiency No concurrent life threaten illness PRIOR CONCURRENT THERAPY : Biologic therapy Prior vaccine , antibody , cytokine , small molecule cell signal inhibitor allow Chemotherapy No prior cytotoxic chemotherapy unresectable metastatic pancreatic cancer Endocrine therapy Not specify Radiotherapy See Disease Characteristics More 4 week since prior radiotherapy recover No concurrent radiotherapy Surgery More 3 week since prior surgery recover Other More 3 week since prior noncytotoxic treatment regimen objective evidence progressive disease No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>